Comparative analysis of the use of technetium-99m labeled recombinant target molecules at doses of 1000 and 2000 μg for radionuclide diagnostics of HER2-positive breast cancer. Вопр. онкол. [Internet]. 2022 Feb. 28 [cited 2026 Oct. 14];68(1):60-5. Available from: https://voprosyonkologii.ru/index.php/journal/article/view/1356